The global pipeline of new medicines for the control and elimination of malaria by Melinda P Anthony et al.
Anthony et al. Malaria Journal 2012, 11:316
http://www.malariajournal.com/content/11/1/316REVIEW Open AccessThe global pipeline of new medicines for the
control and elimination of malaria
Melinda P Anthony, Jeremy N Burrows, Stephan Duparc, Joerg JMoehrle and Timothy NC Wells*Abstract
Over the past decade, there has been a transformation in the portfolio of medicines to combat malaria. New
fixed-dose artemisinin combination therapy is available, with four different types having received approval from
Stringent Regulatory Authorities or the World Health Organization (WHO). However, there is still scope for
improvement. The Malaria Eradication Research agenda identified several gaps in the current portfolio. Simpler
regimens, such as a single-dose cure are needed, compared with the current three-day treatment. In addition, new
medicines that prevent transmission and also relapse are needed, but with better safety profiles than current
medicines. There is also a big opportunity for new medicines to prevent reinfection and to provide
chemoprotection. This study reviews the global portfolio of new medicines in development against malaria, as of
the summer of 2012. Cell-based phenotypic screening, and ‘fast followers’ of clinically validated classes, mean that
there are now many new classes of molecules starting in clinical development, especially for the blood stages of
malaria. There remain significant gaps for medicines blocking transmission, preventing relapse, and long-duration
molecules for chemoprotection. The nascent pipeline of new medicines is significantly stronger than five years ago.
However, there are still risks ahead in clinical development and sustainable funding of clinical studies is vital if this
early promise is going to be delivered.
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Recent years have seen a transformation in the landscape
of malaria drug discovery and development. A review of
publicly available data from PubMed, clinicaltrials.gov as
well as proprietary databases, such as Thomson Pharma,
revealed that as of March 2012, over 50 projects were in
progress worldwide. These include a wide variety of
molecules in the window between late discovery (within
12 months of starting regulatory preclinical studies) and
launch. Twenty-seven of these are in formal regulatory
studies and beyond. In addition, in the past three years,
five new medicines have either been approved by Strin-
gent Regulatory Authorities [those that adhere to the
guidelines of the International Commission for Harmon-
isation (ICH), or prequalified by the World Health
Organization (WHO)].* Correspondence: wellst@mmv.org
Medicines for Malaria Venture (MMV), 20 rte de Pré-Bois 1215, Geneva,
Switzerland
© 2012 Anthony et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe portfolio of new medicines contains several genera-
tions of products. The oldest group reflects the requirement
for fixed-dose, artemisinin-combination therapy (ACT),
driven by the need to protect artemisinin from the emer-
gence and spread of resistance. This therapy is based
around active molecules that were first identified over
30 years ago. The central focus for the development process
of this therapy has been ensuring that the historical data
available match current international standards of safety
and efficacy.
The call for the eradication of malaria in 2007 led to a
new research agenda [1] laying out priorities with
broader horizons. As well as the focus on case manage-
ment of uncomplicated and severe malaria, there is now
a need for medicines that prevent transmission, stop re-
lapse and provide chemoprotection against new infec-
tions. These characteristics are described by Target
Product Profiles (TPPs), which give a description of the
ideal medicine and the minimum acceptable profile.
TPPs provide drug discoverers with a common standard
of the unmet clinical needs in malaria control andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developed with input from countries, field-based clini-
cians, and discovery and development teams [2], and are
refined every two years [3].
Methodology
This review aims to be as complete as possible, and not
simply to be a review of projects supported by Medicines
for Malaria Venture (MMV). To obtain such a global
view, the data were obtained from publicly available
sources, such as Medline, clinicaltrials.gov, and company
websites, supported by commercial databases, such as
Thomson Pharma (www.thomson-pharma.com). There is
unfortunately insufficient space to cite every single source.
The data were updated in March-April 2012, although it
is appreciated that the picture is continually evolving.
Controlling malaria: artemisinin combination therapy as
first-line treatment
Today, first-line medicines against malaria are fixed-
dose artemisinin combination therapy (ACT). These
medicines are assumed to be active against the blood
stages of all of the major forms of Plasmodium which
infect humans: falciparum, vivax, malariae, ovale and
knowlesi. Fixed-dose combination therapy has the ad-
vantage over co-blistered presentations in that it elimi-
nates the potential for monotherapy [4], which is to be
avoided since it risks the emergence and selection of
resistant parasites [5]. Six of these have been reviewed
by regulatory authorities throughout the world (see
Table 1, Figures 1 and 2). Artemether-lumefantrine
(CoartemW and CoartemW Dispersible from Novartis),
artesunate-amodiaquine (Coarsucam™/Artesunate Amodia-
quine-WinthropW from Sanofi), pyronaridine-artesunate
(PyramaxW from Shin Poong Pharmaceuticals) and meflo-
quine-artesunate from Cipla/DNDi– have been prequalified
by WHO [6]. Their launch has had a dramatic impact on
the number of courses of treatment available to malaria
patients. There has been rapid growth from 62.3 million
treatments in 2006 to 159.7 million in 2010 (see Figure 2)
although, still, not all medicines reach the patients who
need them [7]. Considerable progress has been made on
price, with the costs of an adult course of treatment falling
to $1.00–$1.40. For infants the price can be as low as $0.30
[8], although in 2011 prices rose due to perceived artemisi-
nin shortages [9].
The two major artemisinin combination therapies are:
(a) Artemether-lumefantrine (CoartemW and the
dispersible paediatric formulation CoartemW
Dispersible from Novartis). Over 500 million
treatments of these medicines have been delivered
since the initial launch in 2002, of which over 100
million are now the dispersible form specificallydesigned for children. Several generic versions of
this medicine have now been produced, including
those prequalified by WHO.
(b) Amodiaquine-artesunate (Coarsucam™ and
Artesunate Amodiaquine WinthropW, from Sanofi).
This was initially approved in Morocco, where it is
manufactured and was prequalified by WHO in
2008.
There are four other types of ACT prescribed for
the treatment of uncomplicated malaria, which are
currently at different stages of registration and
approval.
(a) Dihydroartemisinin (DHA)-piperaquine
(EurartesimW from Sigma-tau) was approved by the
European Medicines Agency (EMA) in October
2011 [43] and is included in the Malaria Treatment
Guidelines this year [44]. New data showing two-
year stability are now available. Prequalification by
WHO and submission in key disease-endemic
countries is expected in 2012. Holley-Cotec produce
another version of DHA-piperaquine (Duo-
CotecxinW) [45], available in many countries, which is
expected to be submitted soon for prequalification.
(b) Pyronaridine-artesunate (PyramaxW from Shin
Poong Pharmaceuticals) was approved by the
Korean Food & Drugs Administration (KFDA) in
August 2011 [46], and was approved by the EMA in
February 2012, under Article 58 [47], where opinion
is given on whether a medicine is suitable for use in
countries where the disease is endemic. This avoids
the obligation to market the medicine in Europe,
and is a decision made in conjunction with WHO,
which has now prequalified the product.
(c) Artesunate-mefloquine (ASMQ) is a fixed-dose
combination produced by Cephalon/Mepha as a
paediatric formulation for commercial markets in
Africa, and by the Drugs for Neglected Diseases
initiative (DNDi) in partnership with Farmanguinhos
for use in Brazil. From 2012, the fixed-dose
combination will be manufactured and registered by
Cipla in India, which will accelerate uptake [48]. WHO
prequalification was obtained in September 2012.
Currently the market price of mefloquine (over
$1,000/kg) makes this combination the most expensive
ACT, however work is ongoing to lower the cost of
manufacturing. A cheaper synthesis of mefloquine has
been developed by Development Chemicals in
collaboration with DNDi and MMV. This allows a
price similar to other fixed-dose ACT.
(d) Artemisinin-naphthoquine (ARCOW, Kunming,
China) is available in Africa as a one-day treatment.
There are relatively few data available on the
Table 1 Fixed-dose artemisinin combination therapy approved or in development (as of November 2011)
Active ingredients
(adult dose)




Artemether (20 mg), l
umefantrine (120 mg) x 4 b.i.d
Novartis, MMV Launched 2008 CoartemW;
CoartemW-Dispersible
Coartem was launched in 2001.
Coartem Dispersible is a
specific paediatric formulation
with a sweet-tasting flavour.
It is given twice per day for
three days. Coartem Dispersible decreases
gametocytes by 6–8- fold compared
to sulphadoxine/pyrimethamine and
chloroquine. Approved by Swissmedic
in Dec 2008, it received WHO prequalification
in Feb 2009. Four dose strengths are
registered in 83 countries. In Apr 2009,
Novartis received approval from the
US-FDA for Coartem, including a
‘Priority Review Voucher’ (PRV).
a), f) [10-17]
Artesunate (100 mg),
amodiaquine (270 mg) x 2 q.d.
Sanofi, DNDi (MMV) Prequalified 2008 CoarsucamW;
ASAQ-WinthropW
Marketed as Coarsucam in the private
market and ASAQ-Winthrop in the
public markets. Given once per day for
three days. Originally registered in
Morocco, it is now approved in 31
countries (including 25 in Africa)
and prequalified in 2008 by WHO, but
so far has not been submitted to a
Stringent Regulatory Authority.
Stability data now available for
three years in Zone IVb (30°C
and 75% relative humidity),










Available as Duo-Cotexcin since 2005
(approved by Sino-FDA), uses the
active metabolite of artemisinin,
dihydroartemisinin. Given once
per day for three days. Two pivotal
clinical trials led to approval by the
EMA in 2011. Prequalification
expected 2012. Shows superiority
to artemether-lumefantrine in




Shin Poong, MMV Pre-registration PyramaxW Approved by the Korean K-FDA, and by
the EMA, article 58 in Feb 2012.
Prequalified by WHO. Given once
per day for three days. Four pivotal
clinical studies were performed 2007–2009,
with the first regulatory studies on an ACT
in both Plasmodium falciparum and


















Table 1 Fixed-dose artemisinin combination therapy approved or in development (as of November 2011) (Continued)
to artemether-lumefantrine in post-treatment
protection until day 42.
Mefloquine, (200 mg),






ASMQ; Artequin A fixed-dose combination from Farmanguinhos
(Brazil)/DNDi was registered in Brazil in 2008.
Given once per day over three days. Use outside
Brazil should be accelerated by production by
Cipla (India), and Indian registration in 2012.
Prequalified by WHO in September 2012.
Fixed-dose combination called artequin
granules (50 mg artesunate/125 mg mefloquine),
originally registered in Portugal (2003) and now
sold in Africa in commercial markets.
e), b) [34-38]
Artemisinin (125 mg),
naphthoquine (50 mg) x 8 tablets
Chinese Academy of Military
Medical Sciences,
Kunming Pharma Corp
Launched (China) ARCOW Combination of poorly bio-available
artemisinin with naphthoquine. Given
either as a single dose or split twice
within the same day. Clinical studies
are not GCP compliant, and report on a
limited number of patients. Very little
preclinical data available for review.



















Figure 1 Chemical structures of anti-malarials described in Table 1.
Anthony et al. Malaria Journal 2012, 11:316 Page 5 of 25
http://www.malariajournal.com/content/11/1/316efficacy and safety of naphthoquine [49], and the
product has not yet been submitted for approval
either to a Stringent Regulatory Authority or to
WHO. The adult dose of artemisinin is high
(15–20 mg/kg) [50], reflecting the poor
bioavailability of the parent molecule.
Since over 85% of malaria patients are under five
years old, development of child-friendly paediatricformulations remains the priority. CoartemW Dispers-
ible (dispersible artemether-lumefantrine) is the first
example of a taste-masked dispersible ACT, and was
developed in a collaboration between MMV and
Novartis [51]. Two other paediatric formulations are in
development: a granule formulation of pyronaridine-
artesunate is to be submitted in early 2013 [52], and a
dispersible formulation of DHA-piperaquine is planned
for submission later in the same year.
Figure 2 Sales (USD) of fixed-dose artemisinin combination therapy 2006–2010. These data are compiled from estimates supplied by the
WHO-prequalified manufacturers and from data provided by AMFm and include only WHO-prequalified or Global Fund-approved generic
versions of the medicines. Sales of DHA/piperaquine have been around two million per year, and naphthoquine artemisinin around one million
per year. Mefloquine-artesunate numbers are significantly lower. These numbers compare well with the lower range of the estimates predicted
by the Clinton Foundation [42]. The total number of malaria patients was estimated by WHO to have fallen to 225 million in 2009 [7].
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Each medicine will have a different impact, depending
on the endemicity of the disease, the likelihood of re-in-
fection, diet, co-medications, and the balance between
the different forms of malaria: falciparum, vivax, malar-
iae, ovale or knowlesi. These factors are summarized in
Table 2. Resistance to partner drugs has already oc-
curred in some countries, as has been demonstrated for
amodiaquine [53], and this remains a threat for other
therapy partners in many countries. Clinical signs of de-
creasing effectiveness of partners have been described,
and loss of susceptibility to artemisinin has been
reported in the Thai-Cambodia border regions [54,55] as
well as more recently in the Thai-Myanmar border re-
gion [56]. Having multiple first-line therapies in a coun-
try may help reduce the spread of resistance [57,58].
Pyronaridine-artesunate is currently the only ACT
with regulatory approval for activity against P. vivax, al-
though it is widely assumed from field experience that
other fixed-dose combinations will be equally active
against P. malariae and the blood stages of P. vivax and
P. ovale [31,32].
What challenges remain for the next generation of
medicines? There is a continual threat of the emergence
of resistance, both to artemisinin and the partner medi-
cine. This will require new classes of medicines. In
addition to this there are four areas of focus for drug
discovery. Firstly, in the context of malaria eradication,
there is a need for medicines that can be administered
as a single dose, which will allow direct monitoring of
administration and improve compliance. These should
have activity against all existing resistant strains ofparasite. Secondly, new medicines are needed that kill
gametocytes, and thus prevent transmission. Thirdly,
there is a need for medicines which prevent relapses of
P. vivax. Finally there is a need for molecules with
longer half-lives to give chemoprophylaxis or long-term
protection against re-infection [58]. Figure 3 highlights
the global portfolio of anti-malarial medicines in devel-
opment organized by development stage (as of March
2012). Figure 4 shows the global portfolio of anti-
malarial medicines organized by therapeutic type, as dis-
cussed below.
New treatments for severe malaria
In 2010, a study in African children with severe malaria
[61] showed a significant reduction of mortality using intra-
venous or intramuscular injections of artesunate in place of
quinine, confirming earlier results in adult patients from
Asia [62,63]. WHO now recommends artesunate as a first-
line therapy in severe malaria [44]. ArtesunW(a for injec-
tion), manufactured by Guilin Pharmaceuticals (see Table 3),
was the first to be prequalified by WHO in 2010 [6]. The
cost of approximately $1.00 per treatment is justified by the
better outcome compared with quinine [64]. As with ACT,
it is important that there are multiple and reliable pro-
duction sources, otherwise countries are reluctant to
change treatments. IPCA manufactures artesunate for in-
jection for India (see Table 4), and is planning to submit
for prequalification.
Other therapies for severe malaria are in the pipeline.
Most are adjunctive therapy, given on top of a schizonti-
cide to reduce the sequelae of severe malaria, such as
neurological damage. The track record of most potential






































by the CHMP in Jun 2011,
and EU in Oct 2011
EMA Submitted. Approved
by the Korean FDA
in Aug 2011; approved by














Tablet (adult, child), dispersible
formulation for children
(submission in 2014)
Tablet (adult), sachet with
granules (child),
(submission in 2014)
Tablet (adult, child) Tablet (adult, child)





First line therapy in
francophone Africa.
Three-year shelf life.
Once per day, three
days. Paediatric dose.
Once per day, three-day
treatment course.
























Previous concerns on stability,
but data now support
two years under Zone
IVb conditions
Tablets can only be given
to patients >20 kg.




Psychiatric and GI adverse
events. Mefloquine-resistant
strains exist. Concern
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to highest weight band).
Final price may be higher
due to artesunate prices
Currently at $2.50 per adult.
New mefloquine synthesis
should make the price similar
to other ACT


















Figure 3 The global portfolio of anti-malarial medicines under development organized by development stage (as of March 2012). This
includes all projects in formal regulatory preclinical safety and pharmacokinetic studies. Projects carried out in collaboration with MMV are shown
in open boxes, whereas those with no active MMV involvement are shown with a dashed border. Data are from MMV internal reports [59], and
Thomson Pharma. Compounds have been defined as ‘on hold’ when no significant progress along the development process has been made
publicly available in the last 12 months. Natural products are defined as Herbal Medicinal Products undergoing testing in malaria patients in GCP
quality studies, using standardized extracts. Updates of this figure are available on a quarterly basis [60]).
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ising results in rodent studies. Adjunct approaches have
generally shown little benefit. Recent reports on mole-
cules such as N-acetyl cysteine [123] and pentoxifylline
[124] failed to show any significant benefit. One interest-
ing example of adjunct therapy is DF-02 (sevuparin so-
dium), a heparin derivative with no anti-coagulation
activity that blocks rosetting (a key event in severe mal-
aria [68]), which has just completed Phase I trials. The
only other molecule specifically being developed for this
indication is a TLR-9 antagonist (E6446) from Eisai
[125,126]. One success has been sublingual sucrose,which overcomes hypoglycaemia and, in a pilot study,
resulted in a significant reduction in mortality [79].
The only new schizonticide specifically being pro-
posed for severe malaria is SAR97276 (albitiazolium
bromide), a choline antagonist [71,127]. It is being
positioned in severe malaria because of its poor oral
bioavailability. Phase II trials have shown higher
doses are likely to be needed, at least for uncompli-
cated malaria [128]. However, given the size of the
clinical trials required to show at least non-
inferiority regarding mortality compared to artesu-
nate, no new product is likely to be developed for
Figure 4 The global portfolio of anti-malarial medicines organized by therapeutic type. Compounds have been defined as ‘on hold’ when
no significant progress along the development process has been made publicly available in the last 12 months. This analysis is important to
show the emergence of new classes of medicines. Updates of this figure are available on a quarterly basis [60]).
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mised by resistance in many countries.
The remaining medicines for severe malaria are all
formulations of artemisinin derivatives. An intra-
muscular artemether is included in WHO’s treatment
guidelines and is produced by Kunming and Sanofi,
amongst others (Table 3). No prequalified drug is
available yet though, and there is a question mark
over neurotoxicity as seen in preclinical trial animal
species, but never confirmed in humans [129]. A sub-
lingual spray of artemether from Eastland Medical Sys-
tems Ltd/Proto Pharma is being developed, but there is
the risk that this product is most likely to be used as
monotherapy treatment of uncomplicated malaria, in
contradiction to WHO guidance. Finally, the UNICEF-
UNDP-World Bank-WHO Special Programme for re-
search and training in Tropical Diseases (WHO-TDR) is
developing artesunate suppositories as pre-referral
treatment for patients with severe malaria, enabling
them to receive at least some treatment prior to arrival
at hospital. Clinical studies involving 12,068 patients
showed that this increased the probability of survival of
patients more than six hours away from hospital and for
the youngest patients (100 mg dose) [66]. This product
still needs to be approved by a Stringent Regulatory Au-
thority and/or WHO prequalification, and will require a
partner for manufacture and distribution. Adequate dis-
tribution of these suppositories to health centres morethan six hours away from hospital will pose a significant
challenge.
New products in pregnancy
In areas of high transmission, such as sub-Saharan Af-
rica, malaria in pregnancy is a key cause of maternal,
perinatal and neonatal morbidity. Case management of
malaria seems possible with ACT in the second and
third trimesters. Use of artesunate in the first trimester
is contraindicated because of the side effects seen in pre-
clinical safety models [130], although these effects have
not yet been seen in the registries of patients who were
accidentally treated with ACT during pregnancy [10].
The correct dosing of ACT in pregnancy needs to be
better defined, as studies show that current doses may
be inadequate [131-133]. As well as treatment, medi-
cines may be used for intermittent preventive treatment
in pregnancy (IPTp) to reduce infections and improve
pregnancy outcomes. Options for therapy include azi-
thromycin-chloroquine, mefloquine and also DHA-
piperaquine (Table 4). Azithromycin has poor activity
against malaria, but synergizes with chloroquine, such
that the combination kills even chloroquine-resistant
strains [75]. Similar clinical synergy has been seen be-
tween azithromycin and quinine [74]. This combination
is antibacterial, potentially reducing the risk for new-
borns and mothers from sexually transmitted bacterial
infections [134]. Studies are on-going with another
Table 3 Products under development for severe malaria, or as artemisinin monotherapy
Active
ingredients











analyses: patients >6 hours
from hospital, and <6 years
old. No manufacturing or





Dilafor AB Phase IIa Heparin analogue with a low
anticoagulant activity. Phase I
data were reported in Oct 2009
with doses as high as 420 mg.




Guilin Pharmaceutical WHO prequalified 2010 Artesunate for injection has been
produced since 1987. In 2010,
Guilin gained WHO prequalification
(with support from MMV). The
clinical data in both the Aquamat
and Seaquamat studies used Guilin
material. Current price is $1.40 per







Launched (India) 2011 ARH1, an injectable formulation of
arteether (ethyl ether derivative of
artemisinin). It is oil soluble, has a
long elimination half-life (greater
than 20 hours), and is more stable
than other artemisinin compounds:




Sanofi/CNRS Phase II Bisthiazolium choline uptake inhibitor,
not orally bio-available. Being developed
as an intramuscular injection for severe
malaria. Initial Phase II data showed
relatively poor efficacy in uncomplicated
malaria, and may require a higher dose.
Medicine could have the advantage of








An artemether sublingual mouth spray.
A Phase II study was conducted to
compare the efficacy of ArTiMist™
and intravenous quinine in children
infected with severe malaria, or uncomplicated
malaria and gastro-intestinal complications
(NCT01047436). The difficulty is to make sure



















Table 3 Products under development for severe malaria, or as artemisinin monotherapy (Continued)




Eisai Co Ltd Preclinical Toll-like receptor antagonists.
TLR 9 antagonism has been
suggested to suppress
cerebral vascular lesions and
leakage of vascular contents.
The difficulties in interpreting
the murine data mean
additional proof of mechanism
in humans will be needed


















Table 4 New products under development
Active
ingredients







AZCQ Phase III Azithromycin is a
macrolide requiring
2000 mg/day to be
effective as monotherapy
but shows clinical synergy
with chloroquine even
where chloroquine
resistance is as high




pregnancy (IPTp) in Oct
2010. The primary outcome
is a reduction in the number
of subjects with suboptimal
pregnancy outcome, and





Studies by Institute of
Tropical Medicine,




An antibacterial with activity
against malaria. Early data
in children showed similar
efficacy to amodiaquine
artesunate. A Phase III study
comparing against SP and
DHA-piperaquine is expected
to be completed in Jul 2014.
A Phase III study with 1,714
subjects in Zambia is testing
its effectiveness as prophylaxis
to prevent malaria in pregnancy,









MMV, Ranbaxy Arterolane maleate +
piperaquine
phosphate
Phase III First generation synthetic
peroxide (trioxalane), given
as one tablet per day for
three days. Arterolane as a
monotheraphy drug showed
lower efficacy than artesunate
with seven days of dosing.
A Phase III trial in India,
Bangladesh and Thailand
is now underway.
The medicine was approved
in India in early 2012.
[81-86]
NCT00362050






peroxide. Phase I showed



















Table 4 New products under development (Continued)
to 1,600 mg as a single dose,
and gives plasma concentrations
with anti-parasite activity up to
72 hours. A Phase IIa study in
P. falciparum and P. vivax patients
was completed in mid-2012.
SSR97193, artesunate Sanofi Ferroquine Phase IIa 4-aminoquinoline active in vitro
against multidrug resistant
P. falciparum. Phase II studies
showed that it is active in
combination with artesunate in
African adults and children. Project
was put on hold, presumably





Jomaa Pharma Ltd Fosclin Phase IIa Fosmidomycin is a DOXP inhibitor,
used in combination with the
antibiotic clindamycin. A study
in children showed good tolerability
and 94% efficacy. A further Phase II






Phase II Methylene blue was originally
suggested by Paul Ehrlich.
The combination MB-CQ is
safe in adults and children
with or without G6PD deficiency.
Local acceptability studies imply
discolouration of urine is not
seen as a major issue.
[97-99]
NITD609 Novartis, MMV Phase IIa
(monotherapy)
Spiroindolone suppresses protein
synthesis in the parasite, working
through PfATP4. NITD609 has the
pharmacokinetic properties
compatible with once-daily oral
dosing for the potential treatment
of falciparum and vivax malaria.





Actelion Phase I A compound of undisclosed
structure with similar parasite
reduction rates as chloroquine.
Completed Phase I
in summer 2012
GNF156 Genome Foundation of Novartis, MMV Preclinical An imidazolopiperazine active
against blood, liver and
gametocytes, with stages of
Plasmodium, and active in murine

















Table 4 New products under development (Continued)
started in the first quarter of 2011,
and Phase I early in 2012.
Oxaboroles Anacor, MMV Preclinical A new class of oxaboroles.
Highly potent against
P. falciparum parasites, and
curative in animal models.
Has a good safety profile and
excellent drug-like properties,
and low cost-of-goods.




Preclinical A dihydroorotate dehydrogenase
(DHODH) inhibitor. In June 2010,
a compound was chosen from
the inhibitor series for full
preclinical development. First in
human studies are planned for
early 2013.
[102-105]
MK4815 Merck, MMV Preclinical A cell-based inhibitor that has
demonstrated potency against
P. falciparum malaria when
tested in vivo. Its mechanism
of action appears to involve
the mitochondrial electron
transport chain of the parasite,
and when administered,
concentrates in infected
erythrocytes. Due to safety




Preclinical A dihydrofolate reductase
inhibitor binds with high
affinity to the wild-type and
resistant DHFR enzymes and
has an excellent ADME-PK
profile. Currently in preclinical
development, although there
are concerns about the impact
of pre-existing DHFR mutant
stains of parasite.
Genz668764 Genzyme Corp (Sanofi), MMV Preclinical An aminoindole, with activity
against both P. falciparum
and P. knowlesi. This family
has the advantage that it
has been impossible so far
to produce resistant mutant
strains of parasite. Preclinical
evaluation started in early 2011.
[106]
RKA 182 Liverpool School of Tropical
Medicine, Liverpool University
Preclinical Lead compound from a series


















Table 4 New products under development (Continued)
anti-parasitic activity. Has
shown anti-malarial activity
against a range of multi-drug
resistant isolates. Its half-life is
intermediate between OZ277
and OZ439. Next-generation
compounds are currently being
tested.
BCX4945 Albert Einstein College of
Medicine, Biocryst
Pharmaceuticals,
On Hold Parasites cultured in human
erythrocytes can be




in the mouse suggest a
mechanism for lack of
in vivo activity, and that
these compounds




CDRI 99/411 Ipca, CDRI On Hold A trioxane anti-malarial
candidate, shown
initially to be safe in
pre-clinical studies.
An IND was approved in
March 2010 in India, but no
further progress has been reported.
[111]
AQ-13 Immtech On hold AQ-13 is another
4-aminoquinoline, active
against chloroquine-resistant
P. falciparum infection. A
Phase I study with 126 individuals
was successfully completed in 2005,
but no further development was










On hold N-tert-butyl isoquine was
developed as a safer
alternative to amodiaquine.
In May 2008, a single-blinded,
placebo-controlled, randomized
Phase I trial was initiated in
healthy volunteers. The trial was stopped
later in 2008 as a result of adverse events,
at the highest dose. Experiments are



















Table 4 New products under development (Continued)
SAR116242/PA1103 Palumed, MMV On hold A fusion compound containing a
trioxane ring and a 4-aminoquinoline
group. It entered preclinical development
in 2007, but has not progressed into
human studies.
[118]







On hold In preclinical studies, artemisone,
a new artemisinin derivative
proposed to have enhanced safety
over artesunate. Currently being
discussed as an option for treating
artemisinin-resistant malaria,
although clinical trials have not
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zole-trimethoprim), in HIV co-infected women, by the
Institute of Tropical Medicine, Antwerp and University
of California, San Francisco, USA (NCT00948896).
The other medicine commonly discussed for IPTp is
mefloquine, which shows significant clinical benefit
[135]. Two complications are side effects and cost. Mef-
loquine causes nausea and neuropsychiatric disorders
amongst Caucasian volunteer cohorts [136], but studies
show that side effects are balanced by the positive influ-
ence of the drug [37]. On-going efforts sponsored by
MMV have optimized mefloquine synthesis, with the po-
tential to lower the cost-per-treatment more than two-
fold to less than $400/kg. The use of ACT in IPTp is
complicated by concerns over the use of artemisinin in
pregnancy, and also the concern over using the same
medicines for prophylaxis and treatment.Next generation endoperoxides
The world demand for artemisinin products is large.
Treating all malaria cases could require in excess of 200
tonnes of artemisinin per year. The price of artemisinin
from plants has fluctuated widely (between $300/kg and
$1,500/kg), and material can take up to two years from
order to delivery. This creates a problem for low-cost
therapy. Three solutions have been proposed: first, the
use of higher-yielding seeds [137]; second, using yeast for
scalable production in bioreactors [138], where Sanofi
plans first commercial tonne-scale production in 2012;
and third, to make synthetic endoperoxides.
MMV established a project with the University of
Nebraska, the Swiss Tropical and Public Health Institute,
and Monash University to develop synthetic endoperox-
ides in 2000. The first clinical product was OZ277 (now
called Rbx11160 or arterolane). This showed activity in
Phase IIa trials [139] in uncomplicated falciparum malaria.
However, the clinical activity was not as good as artemisi-
nin, showing adequate clinical and parasitic response at
day 28 (ACPR28) of 60–70% after seven days’ treatment,
compared with a 95% response with artesunate. The
plasma exposure was non-linear above 100 mg, and
OZ277/Rbx11160 was unstable in infected blood (presum-
ably due to free ferrous iron) [84]. Despite this, Ranbaxy
have completed a Phase III study of OZ277/Rbx11160
(150 mg) and piperaquine (750 mg), and the product has
been approved in India. This is the first medicine to be
developed in India. The lower efficacy of OZ277/
Rbx11160 compared to artesunate [84] may increase the
pressure for resistance against piperaquine, which is
already being reported in Cambodia [140]. MMV’s next-
generation clinical candidate, OZ439, has superior
pharmacokinetics: exposure is dose-proportional,
similar in patients and volunteers, and plasmaconcentrations remain above the mean parasiticidal
concentration for more than 72 hours after a single
dose, suggesting it could be part of a single-dose cure
[84]. Phase IIa studies in uncomplicated P. vivax and
P. falciparum malaria have now been completed. The
next stage is to investigate drug interactions in volun-
teers with potential partner drugs.
Three other synthetic endoperoxides have been in pre-
clinical development (Table 4). RKA 182 is a tetraoxane,
from the Liverpool School of Tropical Medicine and the
University of Liverpool, with a simpler, more symmetrical
molecule that may have a lower cost-per-treatment. Pre-
clinical testing showed it to be superior to OZ277 [107],
and further work is ongoing to identify a molecule with
pharmacokinetics similar to OZ349. CDRI 99/411[141]
from the Central Drug Research Institute in India was
taken into Phase I by IPCA but the project is currently
on hold. A trioxalane (a six-membered endoperoxide
ring), fused with a 4-aminoquinoline, was produced by
Palumed (PA1103/SAR116242) [118], but was aban-
doned in preclinical development. Finally, the semi-
synthetic endoperoxide, artemisone, showed good activ-
ity in Phase II studies in 2009 [121]. Potential advantages
of artemisone include lower dose and potential activity in
artemisinin-resistant malaria (given the additional thio-
morpholino ring). Initially the compound was developed
by Bayer, however the company is no longer involved
with this molecule and a new partner is needed before
clinical studies can recommence.
Preventing the relapse of Plasmodium vivax malaria
The current gold standard for preventing relapse in P.
vivax or P. ovale is primaquine, an 8-aminoquinoline
[142]. There are two major issues with its use: 14 days’
treatment is required, reducing compliance to close to
zero [143], and there is an elevated risk of haemolysis in
patients with glucose-6-phosphate dehydrogenase (G6PD)
deficiency [142], present in 10–20% of the population in
malaria-endemic areas [144].
The only molecule currently in clinical development
for preventing relapses is tafenoquine (WR 238605), an-
other 8-aminoquinoline originally developed by the
Walter Reed Army Institute of Research. Tafenoquine
has a longer half-life in man, with potential as a single-
dose treatment [144-146]. The clinical programme is
being partnered by GSK and MMV and has now started
recruiting patients for a Phase II dose-finding study. Initial
results on both the relative efficacy and safety in G6PD-
deficient subjects, compared with chloroquine alone or
compared to primaquine, are expected towards the middle
of 2013. NPC1161B is a related 8-aminoquinoline from
the University of Mississippi [147], active against relapses
in primate models. At this stage, it is difficult to find any
superiority of NPC1161B over tafenoquine, apart from its
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preclinical model for G6PD-dependent erythrocyte de-
formation and haemolysis.
Other products in clinical development
The remaining projects in development fall into several
distinct groups:
(a)Next-generation aminoquinolines. There are a
number of 4-aminoquinolines or amino-alcohols in
development. These are positioned as the next-
generation molecules after the current ACTs. As
there are already six artemisinin combination
products with some form of regulatory dossier, and
all have ACPR28 >95%, this makes the hurdles
extremely high for such new molecules. A prime
advantage would be to have molecules with better
safety profiles, but it is almost impossible to predict
this pre-clinically. A lower clinical dose could be an
advantage (total doses of 1,920 mg lumefantrine,
1,620 mg amodiaquine or 2,880 mg piperaquine are
required over three days for adults [44]), especially if
this could be given as a single dose. Phase II studies
have been completed on ferroquine (from Sanofi) in
combination with artesunate, where total doses as
low as 300 mg have shown clinical activity (see
Table 4). Naphthoquine (from Kunming) is used in a
dose of only 400 mg in the combination with
artemisinin, and both of these compounds show
some promise. Two other aminoquinolines are on
hold: AQ-13 is a modified chloroquine, showing
similar exposure in Phase I [147], but which is not
sufficiently differentiated. N-tertiary-butyl isoquine
is a modified amodiaquine from the University of
Liverpool and the Liverpool School of Tropical
Medicine [115,116], which has not been progressed
since the end of Phase I studies.
(b)Antibiotic combinations. In addition to the
azithromycin-chloroquine and sulphamethoxazole-
trimethoprim combination discussed above in the
pregnancy section, two other antibiotic-containing
combinations are being explored (see Table 4). The
1-deoxy-D-xylulose 5-phosphate (DOXP) inhibitor,
fosmidomycin, has been developed with the
lincosamide antibiotic, clindamycin, by Jomaa
Pharma GmbH (NCT00217451). Fosmidomycin
appears to have a rapid parasite-killing activity in
adult patients, but not in children, although a full
time-course has not been published, and the dose of
3,600 mg/day may ultimately be problematic [149].
Antibiotic combinations could be considered as fall-
back therapy in the event that artemisinin resistance
becomes a significant clinical issue. Under these
circumstances, the standard of care could becomeseven days quinine plus antibiotic, and therefore the
barrier to success would be lower. However, as new
classes of molecules enter clinical development from
discovery, the relative importance of these
antibiotics decreases. The major challenge of
effectively managing a portfolio of anti-malarial
medicines is to balance the investment in old classes
of molecules with that in new molecules with
unknown risks and opportunities.
(c)New compounds against molecular targets. Two
compounds against molecular targets have also
moved into development. The enzyme
dihydroorotate dehydrogenase (DHODH) is known
to be essential for the survival of the parasite. A new
inhibitor, DSM1, was identified from high-
throughput screening at the University of Texas,
and the three-dimensional structure of the enzyme-
inhibitor complex has been resolved [103]. An
improved version, DSM265 has recently entered
preclinical development. A next-generation inhibitor
of dihydrofolate reductase, P218, entered preclinical
development, and work has been focused on allaying
fears about the propensity to select for pre-existing
mutations in dihydrofolate reductase (DHFR) from
the widespread use of pyrimethamine [150].
BCX4945, an inhibitor of purine nucleoside
phosphorylase developed for other indications, has
been suggested for use in malaria [110]. However,
the compound showed no activity in mouse models.
(d)New compounds from cellular screens. Despite
these success stories, screening ‘validated’ molecular
targets has not been particularly fruitful over the
past few years, an experience shared with
antibacterial drug discovery [151]. Screening directly
against the whole parasite has, therefore, been
prioritized. Over the past few years, six million
compounds (from over 20 companies and university
groups) have been screened against the parasite in
the intra-erythrocytic stages. This has resulted in
almost 30,000 (0.5%) compounds identified with
activity at micromolar levels [152-154]. This rate is
higher than predicted, and also is higher than that
seen when screening molecular targets. The first
compound to be developed from the parasite-
focused screening is NITD609, a spiroindolone
developed by the Novartis Institute for Tropical
Diseases in Singapore as part of a collaboration with
the Swiss Tropical and Public Health Institute and
the Dutch Biomedical Primate Research Center
[101]. This is now in Phase IIa clinical studies. The
move from screen to Phase IIa within five years is a
tremendous achievement for a new class of
molecules. Target identification in parallel to lead
optimization suggested the P-type cation-
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had been characterized, but not prioritized as a
target [155]. The second compound from this
collaboration is GNF156, an imidazolopiperazine
identified by the Genome Foundation of Novartis in
San Diego as part of the same collaborative network.
It exhibits in vitro potency against blood, liver
schizont and gametocyte stages of Plasmodium, (but
not the hypnozoites), is orally efficacious in mouse
malaria models [156], and has recently entered
human volunteer studies.
Several other molecules coming from similar
screens are entering development. Novel oxaborole-
containing compounds synthesized by Anacor have
been identified by screening their library against
Plasmodium. Genzyme identified an aminoindole in
a project with the Broad Institute in Boston [106],
which is particularly interesting since no resistant
parasite strains have yet been identified. Merck
identified MK4815, also based on cellular assays,
which underwent preclinical evaluation with MMV
and has not progressed further due to a narrow
safety window. Finally, the Swiss biotechnology
company Actelion identified an anti-malarial from a
parasite screen of a highly focused set of molecules,
and this compound is also in Phase I clinical trials.
(e)Other compounds. Methylene blue has long been
known to have an activity against malaria [99],
presumably by changing the redox potential of the
infected cell. Phase IIa studies have been carried out
with other compounds in combination with
chloroquine. The results are interesting, but the
combination therapy is less active than ACT [98].
Recent suggestions of activity against the
gametocytes may require a re-evaluation of its
clinical utility.
Natural products
There is a substantial interest in natural products and
the possibility for their role as new anti-malarials. This is
not a new departure: three of the mainstays of malaria
treatment come from natural products: quinine, lapachol
(which led to atovaquone) and artemisinin. The Chinese
method dao-xing-ni-shi – ‘acting in the reversed order’
– was used by Chen Guofu [157] to investigate herbal
extracts used by a population as their anti-malarial treat-
ment. However, many of the extracts known to ‘cure’
malaria have never been observed in situations where (i)
it is clear that the patients had malaria (defined by
WHO as fever and parasites); (ii) how much of the ex-
tract they consumed; and (iii) whether they had malaria
seven or 14 days later. In addition, given that most Afri-
can adults have some sort of immune protection againstthe malaria parasite, a placebo rate of around 70% is
possible, confounding the studies.
The identification of new active natural products in
malaria has been disappointing [157]. There have been
relatively few new compounds identified by purifying in-
dividual natural product molecules from extracts and
screening them individually against the parasite. This
has led to a call for using molecules in combination
[159], or for a return to more observational clinical stud-
ies [160].
To date, analysis of the literature has found few nat-
ural product extracts in development where the human
data are clear. One is an extract of Nauclea pobeguinii, a
plant from the Democratic Republic of Congo, which
showed a parasite and clinical response of 90.3% at day
14 in 65 patients in Phase II [161]. Although this is
below the WHO threshold, it is a much better result
than would be seen with either a quinine or artemisinin
extract. The second natural product is an extract of
Argemone mexicana (Mexican poppy) from Mali, which
shows a cure rate of 89% at day 28 in Phase II studies
[162]. In both cases, the challenge is to produce standar-
dized extracts for clinical studies. Eventually standar-
dized extracts could become treatments by themselves,
similar to the Indian Ayush-64, the Ghanian Phyto-laria,
and the standard treatment (Argemone mexicana) in
Mali [158]. Moreover, if the active ingredient was identi-
fied, this could be developed into a standardized form.
There is a strong likelihood that the active ingredient
will be a metabolite of the original extract, as these
extracts are relatively weak in in vitro assays. Therefore,
one priority is to analyse the human metabolism of these
interesting extracts.
Significant challenges ahead: changing priorities for the
eradication agenda
The announcement of a malaria eradication agenda and
its subsequent elaboration by various working groups
has helped identify priorities for the future [1]. Beyond
that, new medicines would ideally fit several TPPs (for
more details please see [3]).
(a) Single-dose cure. Not only would changing from a
three-day course of therapy to a single dose
decrease the cost of treatment but also it would
enable directly observed administration, making it
far less easy for patients to take an incomplete
course of treatment. Medicines that are safe enough
to be given as a single dose are needed, that stay at
the site of action for at least two parasite life cycles.
These medicines need to be active against all species
of malaria, especially drug-resistant strains. In
addition, it must be clear that the compounds do
not easily select for resistant phenotypes in strains
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studying artemisinin resistance is the current lack of
stable cell assays and molecular markers, which
make it almost impossible to characterize drug
action.
(b) Transmission-blocking. Preventing the parasite
from being transmitted back to the mosquito in a
blood meal would break the cycle of transmission.
Compounds are being sought that are active against
the gametocyte stage, particularly stage five. In the
next few years, it is hoped that high-throughput
screening will be available to screen larger
collections of molecules specifically for this task.
Understanding the activity of compounds against P.
vivax gametocytes is further complicated by the
lack of stable culture methods, and also because
clinically they appear early in the infection –
transmission may have happened before a patient
seeks medical attention.
(c) Hypnozoite treatment and relapse prevention. For
P. vivax and P. ovale, an additional hurdle is to
prevent relapse of the hypnozoite or dormant liver
form. Attempts are underway to develop biological
assays for efficacy, and first successes have been
achieved [163]. The availability of an assay means
that it is now possible to profile new chemical series
to see whether they have activity against both the
blood and the liver stages. This has led to some
success in hits-to-leads chemistry, which shows
activity against hypnozoites.
(d) Chemoprevention. The most advanced vaccine
against malaria is the RTS,S vaccine (currently
planned for launch in 2015 for children, which
caused a 50% reduction in incidence of acute
falciparum infections in young children in initial
Phase III studies [164-166]). There remains a
significant need for a molecule which can protect
the adult population from infection. As malaria
becomes less common in Africa, the natural
immunity within the population will fall, and the
continent’s population would be as at risk of malaria
infection as western travellers are today. New
protective medicines will need long half-lives. Depot
formulations are possible, but then the medicines
must be potent with a human daily dose of less than
10 mg, and preferably less than 1 mg.
Not all molecules meet all criteria above, as new malaria
medicines will be a combination of several active ingredi-
ents. Understanding the activity of the compounds against
each stage in the Plasmodium life cycle (a Malaria Life-
cycle Fingerprint) is important as early as possible in the
development process to allow a focused development
strategy and prioritization between molecules.In addition, three factors are critical for the development
of new medicines. First, safety and tolerability; since these
medicines will be used in areas where pharmacovigilance
systems are not always completely effective. Second, an
appropriate speed of action; for blood stage medicines, the
patients have become used to the speed of action of arte-
misinin. Third, medicines need to be potent; many of the
current medicines are active at adult doses approaching
1 g per day. If the next-generation of medicines are more
potent, this can greatly impact the cost of treatment. Cost
reductions will be much more likely to come from doses
that are lower than current therapy, rather than from sim-
pler, cheaper molecules.
Conclusions
The pipeline of new molecules targeting malaria is much
richer now than it was two years ago [167]. Two signifi-
cant events have occurred: first, new medicines have
moved down the pipeline, specifically the prequalification
of artesunate for severe malaria and the stringent regula-
tory approval of DHA-piperaquine and pyronaridine-
artesunate as new fixed-dose anti-malarials. Second, and
arguably more interesting, is the number of new mole-
cules and new classes of molecules that are entering the
pipeline. There are at least seven new compound families
that have been discovered in the past five years. This is a
rich portfolio and reflects the commitment of the field as
a whole. Nonetheless, from a portfolio point of view there
are still gaps. The chance that a new molecule entering
Phase I studies will make it to registration is still around
20% for anti-infectives, and for a new combination two
molecules would be needed. In addition, new TPPs have
emerged from the malaria eradication agenda and com-
pounds need to be measured against these, focusing on
transmission-blocking and anti-relapse potential. With the
sustained commitment of all of partners – donors, scien-
tists, academics and the pharmaceutical industry – the
next decade will be a very exciting time to be in clinical
development of new therapeutics for malaria.
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